Please wait...
About This Project
OncoSynergy, Inc.
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Recent Lab Notes From This Project
Browse Other Projects on Experiment
Related Projects
Why do wolverines need snow?
A warming climate in the Arctic is having profound impacts on species that rely on snow and ice, like the polar...
How do we keep wild rhino populations growing during a poaching crisis? The final countdown
African rhinos are of great economic and ecological importance within their range states,but are threatened...
A noninvasive approach to monitor the health of Maine's black bear population
For over 40 years, state biologists have guided black bear management in Maine using data collected from radio...
